Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
Status:
Completed
Trial end date:
2022-04-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the potential for pegloticase with methotrexate (MTX)
to increase the response rate seen with pegloticase alone, and to characterize the safety,
tolerability and pharmacokinetics (PK) of the concomitant use of pegloticase with MTX, by
comparing pegloticase co-administered with MTX to pegloticase co-administered with placebo
for MTX in adults with uncontrolled gout.